Berber Piet

2.6k citations

32 papers · 1.8k · 1 hit paper · h-index 12

Impact in

Immunology top 2%
- Immune Cell Function and Interaction
- IL-33, ST2, and ILC Pathways
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
Immunology and Allergy top 5%

Papers in

Oncology 17
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 3
- Lung Cancer Research Studies 3
- Colorectal Cancer Treatments and Studies 2
Immunology 15
- Immunotherapy and Immune Responses 9
- Immune Cell Function and Interaction 8
- T-cell and B-cell Immunology 5

Co-authors: Hergen Spits (1 shared paper)Jenny Mjösberg (1 shared paper)Sara Trifari (1 shared paper)Tom Cupedo (1 shared paper)Charlotte P. Peters (1 shared paper)Wytske J. Fokkens (1 shared paper)Natasha K. Crellin (1 shared paper)Cornelis M. van Drunen (1 shared paper)
Journals: Frontiers in Immunology (3 papers)British Journal of Clinical Pharmacology (2 papers)Nature Immunology (2 papers)Clinical Cancer Research (1 paper)British Journal of Cancer (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Berber Piet

28 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 2011 · 931 citations

Peers

Countries citing papers authored by Berber Piet

Since Specialization

Citations

This map shows the geographic impact of Berber Piet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berber Piet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berber Piet more than expected).

Fields of papers citing papers by Berber Piet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berber Piet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berber Piet. The network helps show where Berber Piet may publish in the future.

Co-authors

The 25 scholars most cited alongside Berber Piet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Berber Piet Line = papers co-authored together Berber Piet links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 Nature Immunology ·Jenny Mjösberg, Sara Trifari, Natasha K. Crellin, Charlotte P. Peters, Cornelis M. van Drunen, Berber Piet, Wytske J. Fokkens, Tom Cupedo, Hergen Spits Hit paper breakdown →	2011	931
2	Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells Nature Immunology ·Pleun Hombrink, Christina Helbig, Ronald A. Backer, Berber Piet, Anna E. Oja, Regina Stark, Giso Brasser, Aldo Jongejan, René E. Jonkers, Benjamin Nota, Onur Başak, Hans Clevers, Perry D. Moerland, Derk Amsen, René A. W. van Lier	2016	342
3	CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung Journal of Clinical Investigation ·Berber Piet, Godelieve J. de Bree, Barbara S. Smids-Dierdorp, Chris M. van der Loos, Ester B. M. Remmerswaal, Jan H. von der Thüsen, J M W van Haarst, J. P. Eerenberg, Anja ten Brinke, Wim van der Bij, Wim Timens, René A. W. van Lier, René E. Jonkers	2011	135
4	Trigger-happy resident memory CD4+ T cells inhabit the human lungs Mucosal Immunology ·Anna E. Oja, Berber Piet, Christina Helbig, Regina Stark, David van der Zwan, Hans Blaauwgeers, Ester B. M. Remmerswaal, Derk Amsen, René E. Jonkers, Perry D. Moerland, Martijn A. Nolte, René A. W. van Lier, Pleun Hombrink	2017	110
5	Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC Frontiers in Immunology ·Anna E. Oja, Berber Piet, David van der Zwan, Hans Blaauwgeers, Mark Mensink, Sander de Kivit, Jannie Borst, Martijn A. Nolte, René A. W. van Lier, Regina Stark, Pleun Hombrink	2018	93
6	Programmed Cell Death-1/Ligand-1 PET Imaging PET Clinics ·Sarah R. Verhoeff, Michel M. van den Heuvel, Carla M.L. van Herpen, Berber Piet, Erik H.J.G. Aarntzen, Sandra Heskamp	2019	37
7	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis Frontiers in Immunology ·Harm Westdorp, Mark W. D. Sweep, Mark A.J. Gorris, Frank Hoentjen, Marye J. Boers‐Sonderen, Rachel S. van der Post, Michel M. van den Heuvel, Berber Piet, Annemarie Boleij, Haiko J. Bloemendal, I. Jolanda M. de Vries	2021	31
8	Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells International Immunology ·Simone H. C. Havenith, Si La Yong, Siân M. Henson, Berber Piet, Mirza M. Idu, x Sven D. Koch, René E. Jonkers, Natasja A. M. Kragten, Arne N. Akbar, René A. W. van Lier, Ineke J. M. ten Berge	2012	31
9	Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination Journal for ImmunoTherapy of Cancer ·Lieke L. van der Woude, Mark A.J. Gorris, Inge M. N. Wortel, Jeroen H. A. Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg, Michel M. van den Heuvel, Johannes Textor, Carl G. Figdor, Berber Piet, Willemijn S.M.E. Theelen, I. Jolanda M. de Vries	2022	28
10	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity Drug Safety ·Nikki de Rouw, Berber Piet, Hieronymus J. Derijks, Michel M. van den Heuvel, Rob ter Heine	2021	17
11	Recent Advances and Future Perspective of DC-Based Therapy in NSCLC Frontiers in Immunology ·Iris A.E. van der Hoorn, Georgina Flórez‐Grau, Michel M. van den Heuvel, I. Jolanda M. de Vries, Berber Piet	2021	14
12	Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential Cell Reports Medicine ·Anouk M.D. Becker, A Decker, Georgina Flórez‐Grau, Ghaith Bakdash, Rutger J. Röring, Suzan Stelloo, Michiel Vermeulen, Berber Piet, Erik H.J.G. Aarntzen, Martijn Verdoes, I. Jolanda M. de Vries	2024	14
13	Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer European Respiratory Review ·Leila S. Otten, Berber Piet, Michel M. van den Heuvel, Catia Marzolini, Robin M.J.M. van Geel, Judith L. Gulikers, David M. Burger, Jenneke Leentjens, Rob ter Heine	2022	11
14	Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression Clinical and Translational Science ·Demy A. C. van den Haak, Leila S. Otten, Hans J. P. M. Koenen, Ruben L. Smeets, Berber Piet, Peter Pickkers, Matthijs Kox, Rob ter Heine	2023	10
15	A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer Targeted Oncology ·Rob ter Heine, Michel M. van den Heuvel, Berber Piet, Maarten J. Deenen, Anthonie J. van der Wekken, Lizza Hendriks, Sander Croes, Robin M.J.M. van Geel, Frank G. A. Jansman, R.C. Boshuizen, Eric J. F. Franssen, Arthur A J Smit, Daphne W. Dumoulin, Thijs H. Oude Munnink, Egbert F. Smit, Hieronymus J. Derijks, Cor H. van der Leest, Jeroen J. M. A. Hendrikx, Dirk Jan A. R. Moes, Nikki de Rouw	2023	8
16	Integrating treatment cost reduction strategies and biomarker research to reduce costs and personalize expensive treatments: an example of a self-funding trial in non-small cell lung cancer Frontiers in Pharmacology ·Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel	2023	6
17	Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry European Journal of Immunology ·Iris A.E. van der Hoorn, Evgenia Martynova, Beatriz Subtil, Jelena Meek, Kiek Verrijp, Johannes Textor, Georgina Flórez‐Grau, Berber Piet, Michel M. van den Heuvel, I. Jolanda M. de Vries, Mark A.J. Gorris	2023	5
18	Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy Frontiers in Oncology ·Evelien A. J. van Genugten, Jetty A.M. Weijers, Sandra Heskamp, Manfred Kneilling, Michel M. van den Heuvel, Berber Piet, Johan Bussink, Lizza Hendriks, Erik H.J.G. Aarntzen	2022	4
19	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) Annals of Oncology ·Karin Verkerk, Twan van der Wel, Laurien J. Zeverijn, Birgit S. Geurts, Ilse A.C. Spiekman, G.F. de Wit, Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza Hendriks, Carla M.L. van Herpen, Berber Piet, G. Herder, Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, J. De Langen	2023	3
20	Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome Clinical Lung Cancer ·Anouk M E Jansen, Jincey D. Sriram, Dick Pluim, Rutger Maas, Hester van Groningen, Berber Piet, Rob ter Heine	2020	3

About Berber Piet

Berber Piet is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Molecular Biology and Surgery, having authored 32 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (8 papers), Lung Cancer Treatments and Mutations (8 papers), T-cell and B-cell Immunology (5 papers), CAR-T cell therapy research (3 papers), Lung Cancer Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Immunology (1.5k citations), Immunology and Allergy (123 citations), Surgery (592 citations), Physiology (346 citations) and Otorhinolaryngology (57 citations). Berber Piet has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Hergen Spits, Jenny Mjösberg, Sara Trifari, Tom Cupedo, Charlotte P. Peters, Wytske J. Fokkens, Natasha K. Crellin, Cornelis M. van Drunen, René A. W. van Lier and René E. Jonkers. Their work appears in journals such as Frontiers in Immunology, British Journal of Clinical Pharmacology, Nature Immunology, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Berber Piet

Impact in

Papers in i

In The Last Decade

Berber Piet

Hit Papers

Peers

Countries citing papers authored by Berber Piet

Fields of papers citing papers by Berber Piet

All Works

About Berber Piet

Explore authors with similar magnitude of impact

Papers in